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Network pharmacology has emerged as a new topic of study in recent years. 
Molecular connectivity maps between drugs and genes/proteins in specific 
disease contexts can be particularly valuable, since the functional approach 
with these maps helps researchers gain global perspectives on both the 
therapeutic and toxicological profiles of drugs. To assess drug 
pharmacological effects, we assume that “ideal” drugs for a patient can treat 
or prevent the disease by modulating gene expression profiles of this patient 
to the similar level with those in healthy people. Starting from this 
hypothesis, we build comprehensive disease-gene-drug connectivity 
relationships with drug-protein directionality (inhibit/activate) information 
based on a computational connectivity maps (CMaps) platform. In this work, 
we develop a novel approach based on integrative pathway modeling. Using 
Alzheimer’s disease (AD) as an example, we identify and rank AD-related 
drugs/compounds with their overall drug-protein “connectivity map” profile. 
First, we retrieve AD-associated proteins through the CMaps platform by 
using “Alzheimer’s disease” as a query term. Second, we retrieve AD-related 
pathways by using those AD-associated proteins as input and searching in 
the Human Pathway Database (HPD) and the PubMed. Third, we integrate 
the AD-related pathways into unified pathway models, from which we 
categorize the pharmaceutical effects of candidate drugs on all AD-
associated proteins as either “therapeutic” or “toxic” (Figure 1). Finally, we 
transform the integrated pathways into network models and rank drugs 
based on the network topological features of drug targets, drug-affecting 
genes/proteins, and curated AD-associated proteins. We demonstrate that 
our approach can help identify AD drug candidates with significant 
therapeutic potentials with small toxic side effects. The case study correlates 
very well with the existing pharmacology of AD drugs and highlights the 
significance of the CMaps platform. Ongoing studies towards this direction 
also have the potential of changing future process of AD drug development. 
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Figure 1. Illustration of drug pharmacological effects based on directionality information for 
drug-protein pairs 
 
 
